Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Experimental immunotherapy in chemotherapy-refractory and immunotherapy-refractory metastatic colorectal cancer patients that have progressed, or are intolerant to, Longsurf (TAS-102) +/- Avastin (bevacizumab) or Stivarga (regorafenib) or Fruzaqla (fruquintinib) combining experimental AlloStim with an anti-programmed death ligand 1 (PD-L1) checkpoint inhibitor drug.